What is BridgeBio Pharma's other noncash income (expense)?

BridgeBio Pharma (BBIO) reported other noncash income (expense) of -$306K in Q1 2026.

How has BridgeBio Pharma's other noncash income (expense) changed year-over-year?

BridgeBio Pharma's other noncash income (expense) decreased by 1557.1% year-over-year, from $21K to -$306K.

What is the long-term trend for BridgeBio Pharma's other noncash income (expense)?

Over 2 years (2021 to 2023), BridgeBio Pharma's other noncash income (expense) has grown at a -66.9% compound annual growth rate (CAGR), from -$7.32M to $803K.

BridgeBio Pharma BBIO Other Noncash Income (Expense)

Other Noncash Income (Expense) at other companies

Bristol-Myers SquibbBMY

-$21M-320%

PfizerPFE

——

BioMarin PharmaceuticalsBMRN

——

Roivant SciencesROIV

——

BiogenBIIB

——

ViatrisVTRS

——

Other financials

Income statement

See full

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

See full

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

See full

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

See full

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

See full

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's other noncash income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BridgeBio Pharma's other noncash income (expense)?: BridgeBio Pharma (BBIO) reported other noncash income (expense) of -$306K in Q1 2026.
How has BridgeBio Pharma's other noncash income (expense) changed year-over-year?: BridgeBio Pharma's other noncash income (expense) decreased by 1557.1% year-over-year, from $21K to -$306K.
What is the long-term trend for BridgeBio Pharma's other noncash income (expense)?: Over 2 years (2021 to 2023), BridgeBio Pharma's other noncash income (expense) has grown at a -66.9% compound annual growth rate (CAGR), from -$7.32M to $803K.